GENE ONLINE|News &
Opinion
Blog

Takeda Pharmaceutical
Licensing F-star
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
Asia-Pacific Hereditary Angioedema
Takeda Reveals Positive Data on Takhzyro at EAACI
2022-07-01
China Takeda Pharmaceutical
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
Funding tRNA
tRNA Startup Clinches $24 Million from ARCH, Takeda and 8VC to Fix Protein Mutations
2022-02-25
Asia-Pacific Gene Therapy
Takeda Taps Code Biotherapeutics to Develop Non-Viral Gene Therapies in $2 Billion Biobucks Deal
2022-02-23
Licensing Rare Disease
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2022-01-14
Funding RNA Editing
Korro Bio Raises $116 Million for RNA Editing Program
2022-01-06
Trials & Approvals Organ Transplant
Takeda’s Livtencity Bags FDA Approval for the Treatment of Post-Transplant Infection
2021-11-24
M&A Cell Therapy
Takeda Snags UK-Based Cell Therapy Collaborator to Boost Immuno-Oncology Portfolio
2021-10-27
Licensing Gene Therapy
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
Licensing Gene Therapy
Takeda Embarks On a Billion-Dollar Gene Therapy Deal with Selecta Biosciences
2021-10-08
Takeda Hits the Brakes on Narcolepsy Drug Trials
2021-10-07
Asia-Pacific Stem Cell Therapy
Takeda’s Allogeneic Stem Cell Therapy Becomes First of Its Kind to Be Approved in Japan
2021-09-28
COVID-19 Vaccine
Takeda to Supply 150 Million Doses of Novavax COVID-19 Vaccine to Japan
2021-09-08
Liver Disease
Takeda To Develop Rare Liver Disease Treatments with Genevant in $303M Pact
2021-08-24
1 2 3 4 5
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top